Protara Therapeutics
TARA
32 hedge funds and large institutions have $93M invested in Protara Therapeutics in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 14 closing their positions.
34% more capital invested
Capital invested by funds: $69.2M → $93M (+$23.8M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
26% less funds holding
Funds holding: 43 → 32 (-11)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$2.14M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
+$1.74M |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$218K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$192K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.46M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.28M |
| 3 |
State Street
Boston,
Massachusetts
|
-$729K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$502K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$398K |
TARA Hedge Fund Activity: Q2 2016 in Review
32 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2016, worth a combined $93M — up 34% from $69.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TARA and 3 opened new positions — a net loss of 11 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Deerfield Management, adding an estimated $2.14M. The largest seller was Fidelity Investments, cutting an estimated $3.46M.
- 32 institutional investors held Protara Therapeutics (TARA) as of Q2 2016, down from 43 in Q1 2016.
- Funds reported $93M of Protara Therapeutics stock for Q2 2016, up 34% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q2 2016 and 14 closed out, a net change of -11 holders.
- The largest Protara Therapeutics buyer in Q2 2016 was Deerfield Management, an estimated $2.14M added.
- The largest Protara Therapeutics seller in Q2 2016 was Fidelity Investments, an estimated $3.46M sold.
Based on aggregated 13F filings for Q2 2016.